rs150326506
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The ENST00000003084.11(CFTR):āc.3503A>Gā(p.Asp1168Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000434 in 1,613,186 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Synonymous variant affecting the same amino acid position (i.e. D1168D) has been classified as Likely benign.
Frequency
Consequence
ENST00000003084.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3503A>G | p.Asp1168Gly | missense_variant | 22/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.3503A>G | p.Asp1168Gly | missense_variant | 22/27 | 1 | NM_000492.4 | ENSP00000003084 | P2 | |
ENST00000456270.1 | n.66-11216T>C | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152166Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000798 AC: 2AN: 250718Hom.: 0 AF XY: 0.00000738 AC XY: 1AN XY: 135506
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461020Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726818
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152166Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74332
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 22, 2022 | PP3, PM2, PM3_supporting - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 30, 2017 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 22, 2024 | Variant summary: CFTR c.3503A>G (p.Asp1168Gly) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250718 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3503A>G has been reported in the literature in the compound heterozygous state in an individual affected with a CFTR-Related Disease and in an individual with metabolic alkalosis, as well as in an infant with a CF-screening positive inconclusive diagnosis by newborn screening (e.g. Lucarelli_2015, Esposito_2020, Castaldo_2020). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 32784480, 33260873, 25910067). ClinVar contains an entry for this variant (Variation ID: 53763). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Cystic fibrosis Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 23, 2022 | The p.D1168G variant (also known as c.3503A>G), located in coding exon 22 of the CFTR gene, results from an A to G substitution at nucleotide position 3503. The aspartic acid at codon 1168 is replaced by glycine, an amino acid with similar properties. This variant has been reported in an individual with a CFTR-related disorder; however, clinical details were limited (Lucarelli M et al. Mol. Med., 2015 Apr;21:257-75). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at